The in vitro siRNA-mediated MALAT1 silencing resulted in impaired lung cancer cell motility by altering the expression levels of cell motility-related genes, such as HMMR at pre-mRNA transcriptional level and CTHRC1, CCT4 and ROD1 at post-transcriptional level [15]. This evidence concerns the gene CTHRC1 and lung carcinoma.